Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome

Research output: Contribution to journalArticle

Authors

  • Shalini V. Kaushik
  • Eric P Plaisance
  • Teayoun Kim
  • Edmond Y. Huang
  • A. Jack Mahurin
  • Peter W. Grandjean
  • Suresh T. Mathews

External Institution(s)

  • Auburn University
  • Baptist Family Medicine Residency Program

Details

Original languageEnglish (US)
Pages (from-to)427-434
Number of pages8
JournalDiabetes/Metabolism Research and Reviews
Volume25
Issue number5
StatusPublished - Jul 1 2009
Peer-reviewedYes

Abstract

Background: Fetuin-A, a liver-secreted phosphoprotein and physiological inhibitor of insulin receptor tyrosine kinase, is associated with insulin resistance, metabolic syndrome (MetS), and an increased risk for type 2 diabetes. However, studies on the modulation of circulating levels of fetuin-A are limited. The goal of this study was to determine the effect of niacin administration on serum total- and phosphorylated fetuin-A (phosphofetuin-A) concentrations in individuals with MetS and correlate with changes in serum lipids, insulin sensitivity, and markers of inflammation. Methods: Fifteen sedentary, obese, male participants, who met the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria for MetS, were treated with extended-release niacin (Niaspan) for 6 weeks. Blood samples were obtained before and after treatment with niacin. Results: Serum fetuin-A and phosphofetuin-A concentrations were decreased following niacin administration (p < 0.005). Changes in fetuin-A concentrations were correlated with changes in triglyceride (r = 0.62, p = 0.01) and C-reactive protein (CRP) concentrations (r = 0.58, p < 0.05) after niacin treatment. Changes in high-density lipoproteins (HDL)-cholesterol following niacin intervention were negatively correlated with changes in serum fetuin-A (p < 0.05) and phosphofetuin-A concentrations (p < 0.05). Serum cortisol levels were significantly elevated after niacin administration. Conclusions: Niacin treatment lowers serum total- and phosphofetuin-A concentrations in individuals with MetS, and these changes correlate with the beneficial changes in serum lipids. Because niacin is known to induce insulin resistance, these findings suggest that fetuin-A may not be a mediator of niacin-induced insulin resistance but it may blunt the insulin resistance induced by niacin by decreasing its circulating concentrations.

    Research areas

  • Alpha 2-HS glycoprotein, Fetuin-A, Metabolic syndrome, Niacin, Niaspan, Triglycerides

Citation formats

APA

Kaushik, S. V., Plaisance, E. P., Kim, T., Huang, E. Y., Mahurin, A. J., Grandjean, P. W., & Mathews, S. T. (2009). Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome. Diabetes/Metabolism Research and Reviews, 25(5), 427-434. https://doi.org/10.1002/dmrr.967

Harvard

Kaushik, SV, Plaisance, EP, Kim, T, Huang, EY, Mahurin, AJ, Grandjean, PW & Mathews, ST 2009, 'Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome', Diabetes/Metabolism Research and Reviews, vol. 25, no. 5, pp. 427-434. https://doi.org/10.1002/dmrr.967